Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
239 Leser
Artikel bewerten:
(0)

Bionorica SE: Research results and market successes ensure sales record

Dow Jones received a payment from EQS/DGAP to publish this press release.

DGAP-Media / 2019-03-08 / 13:20 
 
· Urinary tract infections: Bionorica offers effective plant-based 
substitute 
 
· Cannabis: Strong increase in demand for Dronabinol 
 
· Successful marketing authorisations: Major EU countries open their doors 
to Bionorica 
 
*Neumarkt, Düsseldorf, Germany; 8 March 2019 - *Bionorica SE has some 
special research outcomes to report alongside its record-breaking sales and 
recruitment figures for 2018. The market leader in scientifically researched 
natural medicines in Germany and other pharmaceutical markets has proven in 
an internationally published clinical trial1) that its herbal medicine 
Canephron(R) is not inferior to an antibiotic for the treatment of 
uncomplicated urinary tract infections(2). Urinary tract infections (UTIs) 
are one of the most common medical conditions, particularly in women. Acute, 
uncomplicated UTI has been the second most common reason for prescribing 
antibiotics(3) in the outpatient sector yet. 
 
"_Our research results represent a major breakthrough, because we offer 
patients an effective plant-based alternative that is evidence-based and 
acknowledged. We are therefore showing how prescriptions of antibiotics for 
UTIs can be reduced," said_ Professor Michael A. Popp, CEO of Bionorica SE 
at the company's annual results press conference. 
 
*Strong increase in demand for Dronabinol* 
A further milestone for Bionorica, which is based in Bavaria and operates 
worldwide on the basis of a unique research and manufacturing philosophy 
(Phytoneering), has been the significantly higher demand in the last year 
from critically ill patients for the company's product Dronabinol, an active 
ingredient from the cannabis plant. Doctors are prescribing Dronabinol above 
all to relieve chronic pain in patients who have no alternative treatment 
options. So in the last year, in Germany alone, Bionorica supplied around 
19,500 patients with the THC-based prescription-only medicine, an increase 
of 85 % over the previous year(4). In 2018, Bionorica made the cannabinoid 
available to almost 11,000 patients in Austria, Denmark and Switzerland. 
_"We made losses with Dronabinal for over a decade, due to the limited 
market, non-reimbursement by health insurers and the R&D costs involved. 
Nevertheless, we have continued to invest and stay in the market for the 
sake of the many critically ill people who have exhausted all other 
treatment options," says Professor Popp, reinforcing his commitment to 
patients._ 
 
*Record sales year after year* 
Overall, Bionorica, which has won various awards for its innovations and 
strong growth, enjoyed yet another record-breaking result in the last fiscal 
year. In 2018, the Bionorica Group's sales increased to nearly EUR 338 
million, up around 13.8 percent on the previous year(5). This means that 
Bionorica Group has been able to increase sales fivefold in the last 15 
years. 
 
*Market leadership extended in Germany* 
In Germany, pharmacists sold more than 20 million units(6) of the market 
leader's products for the first time last year, mainly Sinupret(R), 
Bronchipret(R) and Imupret(R). Sales of Canephron(R), which has become the 
No. 1 medication in the market for herbal urologicals, were also up. The 
cold preparation Sinupret(R) had a market share of 62.5 percent(7) in the 
sinusitis market in Germany in 2018. On the basis of its sales figures in 
euros, Bionorica was once again identified as one of the most dynamic 
companies in the OTC sector in Germany. 
 
*Exports significantly up, more jobs created in Germany and other countries* 
The Bavarian company enjoyed similar successes in markets in Austria, 
Poland, Russia and other countries. "_In Austria, pharmacists sold 8.2 
percent(8) more units than in the previous year. In Poland we grew by 18.5 
percent(9) compared to our direct competitors," says _Dr Uwe Baumann, Head 
of Global Business and Member of the Executive Board at Bionorica, about the 
company's success story. In Russia, Sinupret(R), Canephron(R) and the 
gynaecological phytotherapeutic preparation Mastodynon(R) are among the 
products most prescribed by doctors in their segment and were able to win 
additional market shares(10). In total, Bionorica exported 45 million units 
overseas last year, an increase of 15.4 percent(11) on 2017. The company, 
which has invested heavily in its research and high-tech production 
facilities in Neumarkt, recruited more staff again in 2018, an increase in 
headcount of 6.2 percent(12). Of the 1,700 people employed by Bionorica 
worldwide, more than 1,000 work in Germany. 
 
*Huge potential: Major EU countries open their doors to Bionorica * 
To be able to significantly increase the contribution margins for R&D, 
Bionorica wants to grow continuously using its own financial resources. The 
forecasts for the sustainably operating company are regarded as excellent. 
In this context, the current success of Bionorica in obtaining marketing 
authorisations in several EU countries, that in the past have tended to be 
protectionist, offers tremendous potential. For example, Bionorica was able 
to get approval for two herbal medicines(13) in the Italian market, which is 
dominated by prescription-only medicines and dietary supplements. It also 
obtained marketing authorisations in France and Spain. Marketing 
authorisations for other preparations are set to be granted in these EU 
countries in the course of the year. Moreover, Bionorica is stepping up its 
activities in Mexico, the second-largest market in Latin America. Within the 
next 12 months, the company wants to introduce phyto-pharmaceutical products 
in Mexico from the respiratory, gynaecological and urological segments. 
Bionorica also sees further potential for Dronabinol in Germany and other 
countries. In Germany alone, there are a large number of patients with very 
severe and in some cases chronic illnesses, who have not received successful 
treatment so far and who could benefit from THC. 
 
*Sources: * 
(1) CanUTI-7 trial https://www.karger.com/Article/FullText/493368 [1] 
(2) Acute, uncomplicated UTIs 
(3) DAZonline, "Multimodale Phytotherapie bei Blasenentzündung", 27.6.2017, 
https://www.deutsche-apotheker-zeitung.de/online-inhalte/e-learning/bionoric 
a/multimodale-phytotherapie-bei-blasenentzuendung/chapter:allBlasenentz%C3%B 
Cndungen [2] (as of 1 March 2019) 
(4) Insight Health ApoFusion, pharmacy sell-in 
(5) Bionorica SAP BW (business warehouse), 2017: EUR 296.9 million sales, 
2018: EUR 337.9* million sales of Bionorica Group (*2018 figures 
provisional, subject to confirmation by auditors) 
(6) Insight Health ApoFusion (pharmacy sell-out sales in units): 20.3 
million units in 2018 
(7) Insight Health ApoFusion (pharmacy sell-out sales in units in the 
sinusitis market) 
(8) Iqvia, pharmacy sell-out sales in units 
(9) Pharma Sequence, pharmacy sell-out sales in units 
(10) Prindex "Drug prescriptions monitoring" 
(11) SAP BW, ex-factory sell-out sales in units (2017: 39 million units sold 
overseas, 2018: 45 million units) 
(12) Internal personnel statistics, headcount as of 31.12. (2017: headcount 
1,635, 2018: headcount 1,736, both worldwide) 
(13) Bronchipret(R) and Klimadynon(R) tablets 
 
*Corporate profile* 
Patients want effective and tolerable medications and so herbal medicines 
are the preferred option. Bionorica, located in Neumarkt in Bavaria's 
Oberpfalz region, is one of the world's leading manufacturers of 
scientifically researched herbal medicines. Doctors, pharmacists and 
patients in more than 40 countries trust in our effective products with few 
side effects. In 2018, the Bionorica Group achieved sales of EUR 337.9 
million*. The company's equity ratio is more than 74 percent. Every day, 
some 1,700 employees at 20 Bionorica locations worldwide work on the 
continuation of this success story, which began in Nuremberg 86 years ago. 
Based on the "phytoneering" strategy, Bionorica decodes the extensive active 
ingredient potential of plants (phytos) using state-of-the-art research and 
technology (engineering). The result: highly effective medicines with few 
side effects. Our research and development priorities involve the treatment 
of symptoms in the respiratory tract, urinary tract, women's health and the 
immune system. Our range also includes products for the liver and for 
treating sleep disorders. 
_*preliminary sales figures for the Bionorica Group, subject to confirmation 
by auditors_ 
 
*Media Contact* 
Bionorica SE 
Lion Pfeufer 
Head of Media and Public Relations 
Kerschensteinerstrasse 11-15 
92318 Neumarkt, Germany 
Tel.: +49 (0)9181/231-7423 
Fax +49 (0)9181/231-67423 
Email: unternehmenskommunikation@bionorica.de 
http://bionorica.de/fuer-journalisten.html 
 
End of Media Release 
Additional features: 
 
Picture: http://newsfeed2.eqs.com/bionorica/784955.html [3] 
Subtitle: Prof. Dr. Michael A. Popp und Dr. Uwe Baumann bei der 
Bilanzpressekonferenz der Bionorica SE am 7. März 2019 in Neumarkt. (c) 
Bionorica SE / Stephanie Winterhalter 
 
Document: http://n.eqs.com/c/fncls.ssp?u=UTOCSQBAWB [4] 
Document title: 2019-03-08_press-confrence_Bionorica_SE_en.pdf 
 
Issuer: Bionorica SE 
Key word(s): Enterprise 
 
2019-03-08 Dissemination of a Press Release, transmitted by DGAP - a service 
of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
784955 2019-03-08 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a2bc44e9ba1d7fc7ad9537b161416554&application_id=784955&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e29b7958530c5f169bdc1a2d276fa244&application_id=784955&site_id=vwd&application_name=news 
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=2fc8e4cdcbc89f110436702b6addf5b8&application_id=784955&site_id=vwd&application_name=news 

(MORE TO FOLLOW) Dow Jones Newswires

March 08, 2019 07:21 ET (12:21 GMT)

© 2019 Dow Jones News
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.